Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthy Living Maldives.
Press releases published on August 26, 2025
PolarityBio Completes Enrollment in the Phase III Pivotal Study of SkinTE for Diabetic Foot Ulcers
GlobeNewswire
·
August 26, 2025
SALT LAKE CITY, Aug. 26, 2025 (GLOBE NEWSWIRE) -- PolarityBio, a clinical-stage biotechnology company focused on addressing unmet needs in wound healing through innovation in autologous regenerative skin multicellular therapy, today announced the …
Odyssey Health, Inc. to Advance Development of its Save A Life Choking Rescue Device
GlobeNewswire
·
August 26, 2025
LAS VEGAS, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTCQB: ODYY) (the “Company” or “Odyssey”), a technology and asset acquisition company focused on developing unique, life-saving medical products is pleased to provide the following update …
CDT Equity Identifies New Biological Target Validating AI-Driven Repurposing Strategy
GlobeNewswire
·
August 26, 2025
NAPLES, Fla. and CAMBRIDGE, United Kingdom, Aug. 26, 2025 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”) today announces that it has successfully identified a new biological target and novel therapeutic indication for its lead …
Adagene to Participate in Two Investor Conferences in September
GlobeNewswire
·
August 26, 2025
SAN DIEGO and SUZHOU, China, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene or the Company”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced that Adagene’s Chief Strategy …
Clearside Biomedical Announces Multiple Presentations on Suprachoroidal Delivery to be Featured at the 25th EURETINA Congress
GlobeNewswire
·
August 26, 2025
- Presentations Highlight the Versatility of Clearside’s SCS Microinjector® Platform for the Treatment of Multiple Retinal Diseases - - CLS-AX Trial Designs in Wet AMD and Diabetic Retinopathy to be Featured in Presentation by Dr. Sobha Sivaprasad - …
Proxygen and EPFL Launch Strategic Collaboration to Advance AI-Driven Glue Discovery
GlobeNewswire
·
August 26, 2025
VIENNA and LAUSANNE, Switzerland, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Proxygen, a global leader in the discovery and development of molecular glue degraders, today announced a strategic research collaboration with EPFL (the Swiss Federal Institute of …
Allarity Therapeutics Granted FDA Fast Track Designation for Stenoparib for the Treatment of Advanced Ovarian Cancer
GlobeNewswire
·
August 26, 2025
TARPON SPRINGS, Fla., August 26, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor …
InnovAge to Announce Fourth Quarter and Fiscal 2025 Financial Results and Host Conference Call Tuesday, September 9, 2025
GlobeNewswire
·
August 26, 2025
DENVER, Aug. 26, 2025 (GLOBE NEWSWIRE) -- InnovAge Holding Corp. (“InnovAge” or the “Company”) (Nasdaq: INNV), an industry leader in providing comprehensive healthcare programs to frail, and predominantly dual-eligible seniors through the Program of All- …
Global Healthcare Dispensing Systems Market to Reach USD 6.27 Billion by 2030 | MarketsandMarkets™
GlobeNewswire
·
August 26, 2025
Delray Beach, FL, Aug. 26, 2025 (GLOBE NEWSWIRE) -- The global healthcare dispensing systems market, valued at US$4.36 billion in 2024, stood at US$4.61 billion in 2025 and is projected to advance at a resilient CAGR of 6.3% from 2025 to 2030, culminating …
Vor Bio to Participate in Upcoming Investor Conferences
GlobeNewswire
·
August 26, 2025
CAMBRIDGE, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it will participate in the following upcoming investor conferences: …
Legend Biotech to Participate in the Morgan Stanley Global Healthcare Conference
GlobeNewswire
·
August 26, 2025
SOMERSET, N.J., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced that Ying Huang, Ph.D., the company’s Chief Executive Officer, will participate in a fireside …
Nasus Pharma Marks NYSE American Listing with Bell Ringing Ceremony
GlobeNewswire
·
August 26, 2025
TEL AVIV, Israel, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) (“Nasus Pharma” or the “Company”), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products to treat emergency medical conditions …
Prime Medicine to Participate in Upcoming Investor Conferences
GlobeNewswire
·
August 26, 2025
CAMBRIDGE, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that company management will …
Compass Therapeutics to Participate in Upcoming September Investor Events
GlobeNewswire
·
August 26, 2025
BOSTON, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (“Compass”) (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today …
Fulcrum Therapeutics to Present at Upcoming Investor Meetings
GlobeNewswire
·
August 26, 2025
CAMBRIDGE, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare …
Incannex Reports Positive Results from Phase 2 Clinical Trial of PSX-001 (Psi-GAD) for Generalised Anxiety Disorder
GlobeNewswire
·
August 26, 2025
MELBOURNE, Australia and NEW YORK, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL) (“Incannex” or the “Company”) is pleased to report positive data from its Phase 2 clinical trial of PSX-001 (formerly Psi-GAD), a psilocybin- …
Ashvattha Therapeutics to Present Late-Breaking Phase 2 DME and nAMD Data at 25th EURETINA Congress
GlobeNewswire
·
August 26, 2025
Company to present topline 40-week Phase 2 study efficacy and safety results of migaldendranib (MGB), a novel first-in-class nanomedicine for DME and nAMD Subcutaneous at-home administration represents a potential paradigm shift from frequent in-office …
Cogent Biosciences Announces Participation in the Citi Biopharma Conference
GlobeNewswire
·
August 26, 2025
WALTHAM, Mass. and BOULDER, Colo., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced its participation in a …
Jupiter Neurosciences Launches Nugevia™ Website and Opens Pre-Orders for Groundbreaking Longevity Supplements
GlobeNewswire
·
August 26, 2025
Targeting the Multi-Trillion Dollar Longevity Market Jupiter, Florida, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” or the “Company”), a clinical-stage pharmaceutical company pioneering therapies for central …
PharmaTher Provides Corporate Update Following FDA Approval of Ketamine (KETARx™)
GlobeNewswire
·
August 26, 2025
TORONTO, Aug. 26, 2025 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the "Company" or "PharmaTher") (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company focused on unlocking the pharmaceutical potential of ketamine, is pleased to provide a …